Mirum Pharmaceuticals is trading 11.15% higher at $96.73 after reporting third-quarter sales above estimates and raising its 2026 sales outlook. - Q3 net product sales were $185.7 million; full-year guidance rose to $715 million–$720 million from $680 million–$700 million. - The earnings report also showed a larger-than-expected loss.